LOXL2 overexpression is observed in many human cancers, including gastric cancer [28], hepatocellular carcinoma (HCC) [29], breast cancer [30], and squamous cell carcinomas [31], and closely associated with their clinical-pathological characteristics and prognosis. This evidence concerns the gene LOXL2 and breast carcinoma.